How were Dyax's earnings last quarter?

Dyax Corp (NASDAQ:DYAX) released its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.96 million. Dyax's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) earnings per share.

What other stocks do shareholders of Dyax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT) , ASML (ASML) , Bank of Nova Scotia (BNS) , DOW (DOW) , Dover Motorsports (DVD) , Novavax (NVAX) , Prudential (PRU) , Standard Chartered (STAN) , Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA) .

NASDAQ:DYAX

Dyax (DYAX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free DYAX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $38.41
▼
$38.41
50-Day Range: N/A
52-Week Range: $14.06
▼
$38.56

Volume: N/A
Average Volume: 5.25 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Dyax alerts:

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Dyax Stock (NASDAQ:DYAX)

Dyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Ad Manward Press

Can't believe it's happening again

We explain how this event works in full right here.

DYAX Stock News Headlines

September 7, 2023 | finanznachrichten.de

Anokion SA: Anokion Strengthens its Senior Leadership with Promotions and New Appointment

September 7, 2023 | finance.yahoo.com

Anokion Strengthens its Senior Leadership with Promotions and New Appointment

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

July 17, 2023 | msn.com

Most immigrants in West Virginia are from these countries

July 17, 2023 | msn.com

Is David Corenswet A Good Fit For Superman? Here's How /Film Readers Feel

July 17, 2023 | msn.com

Most immigrants in Virginia are from these countries

July 11, 2023 | benzinga.com

Cytophage Technologies Inc. Board of Directors Welcomes New Member and Board Advisor

July 7, 2023 | msn.com

Janhvi and Khushi Kapoor shower love Boney Kapoor as he cooks breakfast for Anshula

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

May 16, 2023 | marketwatch.com

Next-Generation Antibody Therapeutics Market Price & News with Share Forecast

May 12, 2023 | marketwatch.com

S-1: NutriBand Inc.

May 10, 2023 | finance.yahoo.com

Korro Strengthens Leadership Team with Appointment of Shelby Walker as General Counsel

March 24, 2023 | insidermonkey.com

Astria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Call Transcript

March 14, 2023 | marketwatch.com

Next-Generation Antibody Therapeutics Market Analysis: Understanding The Current State and Future Trends 2023-2028

March 13, 2023 | marketwatch.com

Next-Generation Antibody Therapeutics Market Outlook and Forecast to 2029 with Top Countries Data

March 8, 2023 | marketwatch.com

Next Generation Antibody Therapeutics Market Size, Latest Trends, Share, Top Players, Revenue and Forecast 2028

March 4, 2023 | msn.com

HOOPS RECAP: In UT’s first full game without Zakai Ziegler, Tennessee fails to hit a shot during the final six minutes of the game, loses to Auburn 79-70

February 26, 2023 | marketwatch.com

Next-Generation Antibody Therapeutics Market Size, Analysis with Key Players having Regional Statistics and Application Forecast to 2028

January 11, 2023 | msn.com

Peter Hotez on new COVID XBB1.5 variant: 'People are saying this will be mild. It's not mild'

January 2, 2023 | thestreet.com

Drug Giant Shire Snaps Up Biotech Dyax for $5.9 Billion

December 24, 2022 | seekingalpha.com

Astria Therapeutics: Tailwinds Building With Novel Treatment Paradigm

December 13, 2022 | msn.com

Noisy toys and hearing damage with Ascent Audiology & Hearing

November 28, 2022 | msn.com

Commentary: There are those who get out of the water when there’s a shark, and those who get in

November 18, 2022 | msn.com

Instagrammer shares how their tiny ‘kitchen composter’ makes food waste disappear: ‘Everyone needs one’

November 17, 2022 | msn.com

No more deaths recorded in Bristol

November 2, 2022 | msn.com

Martin Lewis says thousands being ripped off when it comes to savings rates

October 14, 2022 | seekingalpha.com

KalVista: Another Setback But The Key Value Driver Is Still In Place

See More Headlines

Receive DYAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyax and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/28/2015
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:DYAX
CUSIP: 26746E10
CIK: 907562
Web: www.dyax.com
Phone: +1-617-2505769
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

DYAX Stock Analysis - Frequently Asked Questions

How were Dyax's earnings last quarter?: Dyax Corp (NASDAQ:DYAX) released its quarterly earnings data on Wednesday, October, 28th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The biopharmaceutical company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.96 million. Dyax's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) earnings per share.
What other stocks do shareholders of Dyax own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dyax investors own include (KRFT) (KRFT), ASML (ASML), Bank of Nova Scotia (BNS), DOW (DOW), Dover Motorsports (DVD), Novavax (NVAX), Prudential (PRU), Standard Chartered (STAN), Anthera Pharmaceuticals (ANTH) and Ariad Pharmaceuticals (ARIA).

This page (NASDAQ:DYAX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dyax (DYAX) Stock Price, News & Analysis

About Dyax Stock (NASDAQ:DYAX)

DYAX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

DYAX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info